Altogether, it is possible that narazaciclib could have anti-AML activity through MOAs targeting either FLT3/FLT3-ITD or possibly CSF1R, depending on the genetic/epigenetic compositions of AML patients. Here, FLT3 is linked to acute myeloid leukemia.